Search Result

Isoforms Recommended:	EGFR/ErbB1/HER1

Results for "

EGF-R

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Ack1 (1) Acyltransferase (1) ADC Cytotoxin (1) ADC Linker (1) Akt (22) AMPK (2) Amyloid-β (1) Anaplastic lymphoma kinase (ALK) (9) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (138) Aurora Kinase (2) Autophagy (43) Bacterial (2) Bcl-2 Family (4) Bcr-Abl (2) BCRP (1) BMX Kinase (2) Btk (14) c-Kit (2) c-Met/HGFR (16) Calcium Channel (3) CaMK (2) Casein Kinase (3) Caspase (5) CDK (15) Checkpoint Kinase (Chk) (1) COX (2) Cytochrome P450 (2) Dihydrofolate reductase (DHFR) (4) Discoidin Domain Receptor (1) DNA-PK (1) DNA/RNA Synthesis (2) Drug Intermediate (1) Drug Metabolite (9) Drug-Linker Conjugates for ADC (3) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (2) EGFR (586) Endogenous Metabolite (5) Enterovirus (1) Epigenetic Reader Domain (1) ERK (12) Estrogen Receptor/ERR (1) FAK (5) Ferroptosis (7) FGFR (6) FLT3 (1) Fluorescent Dye (3) GLUT (1) GPR35 (1) GSK-3 (1) HCV (2) HDAC (2) Histone Acetyltransferase (1) Histone Methyltransferase (2) HIV (1) HSP (5) IGF-1R (2) IKK (1) Influenza Virus (2) IRAK (2) Isotope-Labeled Compounds (2) Itk (3) JAK (9) JNK (3) Ligands for Target Protein for PROTAC (3) MDM-2/p53 (1) MEK (1) mGluR (1) Microtubule/Tubulin (4) Mitochondrial Metabolism (1) MMP (3) Monoamine Oxidase (1) mTOR (4) Na+/K+ ATPase (1) Necroptosis (3) NF-κB (1) Orthopoxvirus (2) Oxidative Phosphorylation (1) p38 MAPK (11) PAK (1) Parasite (2) PARP (6) PD-1/PD-L1 (3) PDGFR (9) PGE synthase (1) Phosphatase (6) Phosphodiesterase (PDE) (3) PI3K (6) PI4K (1) Pim (1) PKA (3) PKC (3) Polo-like Kinase (PLK) (1) Potassium Channel (1) PPAR (1) PROTAC Linkers (3) PROTACs (27) Radionuclide-Drug Conjugates (RDCs) (1) Raf (8) Ras (3) Reactive Oxygen Species (7) RET (4) Reverse Transcriptase (1) ROR (1) ROS Kinase (1) RSV (1) Ser/Thr Protease (1) SHP2 (1) Small Interfering RNA (siRNA) (3) SphK (2) Src (15) STAT (8) Survivin (1) TAM Receptor (3) Target Protein Ligand-Linker Conjugates (1) TGF-beta/Smad (1) TGF-β Receptor (1) Thymidylate Synthase (2) Tie (1) Topoisomerase (6) Trk Receptor (4) Tyrosinase (1) VEGFR (38) Wnt (1)
By Research Areas:	Cancer (647) Cardiovascular Disease (12) Infection (9) Inflammation/Immunology (32) Metabolic Disease (5) Neurological Disease (9)
Click Chemistry:	Azide (2) Alkynes (21)
Oligonucleotides:	Aptamers (1) Pre-designed siRNA Sets (3) siRNAs (3)

693

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150611

EGFR-IN-70	EGFR	Cancer
EGFR-IN-70 (compound 18j) is a potent *EGFR* inhibitor with IC₅₀ values of 23.6 and 307.5 nM for EGFR ^LR/TM/CS and EGFR ^WT, respectively. EGFR-IN-70 has anti-proliferative activity and suppresses phosphorylation of the EGFR. EGFR-IN-70 can be used for cancer research .

HY-P3918

EGF-R (661-681) T669 Peptide	p38 MAPK	Others
EGF-R (661-681) T669 Peptide is a MAPK substrate that can used to measure MAPK catalytic activity .

HY-158154

EGFR-IN-110	EGFR	Cancer
EGFR-IN-110 (Compound 6) is a covalent *EGFR* inhibitor, with pIC₅₀ values of 9.2 and 8.7 for EGFR enzyme and EGFR cell, respectively. EGFR-IN-110 shows high EGFR potency and good kinase selectivity .

HY-145823

EGFR-IN-42	EGFR	Cancer
EGFR-IN-42 (Compound 17b) is a potent inhibitor of *EGFR* with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-42 has superior anti-cancer activity .

HY-145824

EGFR-IN-43	EGFR	Cancer
EGFR-IN-43 (Compound 17c) is a potent inhibitor of *EGFR* with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-43 has superior anti-cancer activity .

HY-111452

EGFR-IN-85	EGFR	Cancer
EGFR-IN-85 (Compound 1) is an *EGFR* inhibitor. EGFR-IN-85 has IC₅₀ value of 0.19 μM for EGFRvⅢ phosphorylation. EGFR-IN-85 can suppress EGFR signaling within tumors. EGFR-IN-85 can be used for Glioblastoma (GBM) research .

HY-161537

EGFR ligand-9	EGFR	Cancer
EGFR ligand-9 is an *EGFR* ligand. EGFR ligand-9 can be used for synthesis of PROTAC EGFR degrader 9 (HY-161536) .

HY-156741

EGFR-IN-87	EGFR	Cancer
EGFR-IN-87 is a *EGFR* tyrosine kinase inhibitor. EGFR-IN-87 has IC₅₀ value of 3.1 nM, 1.3 nM and 7.1 nM for EGFR_d746-750, EGFR_L858R/T790 and EGFR_WT in A431 cells, respectively. EGFR-IN-87 can be used for cancer diseases research .

HY-142681

EGFR-IN-28	EGFR	Cancer
EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity .

HY-150905

EGFR ligand-2	EGFR	Cancer
EGFR ligand-2 (compound C4), a covalent *EGFR* ligand, is a EGFR mutant inhibitor with IC₅₀s of 21 nM and 48 nM for EGFR ^L858R and EGFR ^L858R/T790M, respectively. EGFR ligand-2 can be used to synthesize PROTAC .

HY-126320

EGFR-IN-8	EGFR c-Met/HGFR	Cancer
EGFR-IN-8 is a dual *EGFR* and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC .

HY-155074

EGFR-IN-79	EGFR	Cancer
EGFR-IN-79 (compound 21) is an EGFR inhibior with antitumor activity. EGFR-IN-79 induces ROS-independent apoptosis and EGFR/AKT/mTOR-mediated autophagy. EGFR-IN-79 induces cell death at both proliferating and quiescent zones of EJ28 spheroids. EGFR-IN-79 exhibits safety profile in the zebrafish-based model .

HY-17499

EGFR-IN-12	EGFR Apoptosis	Cancer
EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective *EGFR* inhibitor with an IC₅₀of 21 nM. EGFR-IN-12 also inhibits mutant EGFR ^L858R and EGFR ^L861Q with IC₅₀s of 63 nM and 4 nM, respectively. EGFR-IN-12 displays strong selectivity for *EGFR* over HER4 (IC₅₀ = 7640 nM) and a panel of 55 other kinases. EGFR-IN-12 induces cells apoptosis and has antitumor activity .

HY-142678

EGFR-IN-21	EGFR	Cancer
EGFR-IN-21 is a potent *EGFR* inhibtior with an IC₅₀ of 0.38 nM. EGFR-IN-21 has antitumor activity .

HY-146471

EGFR-IN-51	EGFR Apoptosis	Cancer
EGFR-IN-51 (Compound 6) is a potent *EGFR* inhibitor with IC₅₀ values of 0.493, 102.60 and 461.63 µM against EGFR, EGFR L858R-TK and EGFR T790M-TK, respectively. EGFR-IN-51 shows cytotoxic activity against cancer cell lines and induces apoptosis .

HY-146472

EGFR-IN-52	EGFR Apoptosis	Cancer
EGFR-IN-52 (Compound 4) is a potent *EGFR* inhibitor with IC₅₀ values of 0.358, 86.02 and 432.67 µM against EGFR, EGFR L858R-TK and EGFR T790M-TK, respectively. EGFR-IN-52 shows cytotoxic activity against cancer cell lines and induces apoptosis .

HY-162360

EGFR-IN-109	Apoptosis EGFR Caspase Bcl-2 Family	Cancer
EGFR-IN-109 (compound 4) is an EGFR inhibitor, with the IC₅₀ values of 25.8 and 182.3 nM for EGFR ^WT and EGFR ^T790M, respectively. EGFR-IN-109 arrests the cancer cells’ growth at the G2/M phase and induces both early and late apoptosis. EGFR-IN-109 can be used in cancer research .

HY-168559

EGFR-IN-131	EGFR Apoptosis	Cancer
EGFR-IN-131 (compound 3a) is a potent and cross the blood-brain barrier *EGFR* inhibitor with an IC₅₀ value of 272.9 nM. EGFR-IN-131 shows antiproliferative activity. EGFR-IN-131 induces apoptosis and cell cycle arrest at G0/G1 phase. EGFR-IN-131 decreases the protein expression of p-EGFR .

HY-161923

EGFR-IN-120	EGFR Apoptosis Akt ERK	Cancer
EGFR-IN-120 (Compound 11eg) is an orally active *EGFR* inhibitor. EGFR-IN-120 inhibits EGFR ^{L858R/T790M/C797S} with an IC₅₀ value of 0.053 μM, and has a relatively weak effect on EGFR ^WT (IC₅₀: 1.05 μM). EGFR-IN-120 inhibits the phosphorylation of EGFR and main downstream effectors (STAT3, AKT, and Erk). EGFR-IN-120 induces cell cycle arrest and cell apoptosis in EGFR mutant cells. EGFR-IN-120 inhibits the proliferation of the NSCLC cells harboring EGFR ^{L858R/T790M/C797S} with an IC₅₀ of 0.052 μM .

HY-111415

EGFR-IN-5	EGFR	Cancer
EGFR-IN-5 is a *EGFR* inhibitor with IC₅₀s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR ^L858R, EGFR ^L858R/T790M, and EGFR ^{L858R/T790M/C797S}, respectively.

HY-151882

EGFR-IN-73	EGFR	Cancer
EGFR-IN-73 (Compound 3f) is a potent inhibitor for the most common EGFR mutation EGFR Del19 with an IC₅₀ of 119 nM .

HY-18213

EGFR-IN-9	EGFR	Cancer
EGFR-IN-9 (Compound 8) is a potent EGFR kinase inhibitor with IC₅₀s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity .

HY-146782

EGFR-IN-49	EGFR	Cancer
EGFR-IN-49 is a potent and selective *EGFR* inhibitor with IC₅₀s of 65.0 nM and 13.6 nM for EGFR ^T790M and EGFR ^T790M/L858R, respectively. EGFR-IN-49 induces late apoptosis in a dose-dependent manner .

HY-144056

EGFR-IN-39	EGFR	Cancer
EGFR-IN-39 is a potent inhibitor of *EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 2) .

HY-144055

EGFR-IN-38	EGFR	Cancer
EGFR-IN-38 is a potent inhibitor of *EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 4) .

HY-144054

EGFR-IN-37	EGFR	Cancer
EGFR-IN-37 is a potent inhibitor of *EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 7) .

HY-144052

EGFR-IN-35	EGFR	Cancer
EGFR-IN-35 is a potent inhibitor of *EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 11) .

HY-144051

EGFR-IN-34	EGFR	Cancer
EGFR-IN-34 is a potent inhibitor of *EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 12) .

HY-144050

EGFR-IN-33	EGFR	Cancer
EGFR-IN-33 is a potent inhibitor of *EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR* mutations (extracted from patent WO2021185348A1, compound 13) .

HY-149695

EGFR-IN-91	EGFR	Cancer
EGFR-IN-91 (compound 9) is an orally available *EGFR* inhibitor with blood-brain barrier penetrability. EGFR-IN-91 inhibits EGFR ^L858R/C797S and EGFR ^{exon 19del/C797S}, inducing tumor regression in xenograft (PDX) mouse models. EGFR-IN-91 has the potential to inhibit localized and metastatic non-small cell lung cancer (NSCLC) driven by EGFR mutants .

HY-128862

EGFR-IN-7	EGFR	Cancer
EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC₅₀ values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation *EGFR*-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-152144

EGFR-IN-75	EGFR	Cancer
EGFR-IN-75 is an EGFR ^WT and EGFR ^T790M inhibitor with IC₅₀ values of 0.28 μM and 5.02 μM, respectively. EGFR-IN-75 shows anticancer and antioxidant activity .

HY-151981

EGFR-IN-74	EGFR	Cancer
EGFR-IN-74 (Compound 21) is a potent *EGFR* inhibitor with an IC₅₀ of 138 nM against EGFR L858R/T790M. EGFR-IN-74 induces cancer cell apoptosis .

HY-157432

EGFR-IN-97	EGFR Apoptosis	Cancer
EGFR-IN-97 (compound 6q) is a *EGFR* inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR ^{L858R/T790M/C797S} and Ba/F3-EGFR ^{Del19/T790M/C797S} cells, with IC₅₀ values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR ^{L858R/T790M/C797S} cells at the concentration of 0.8 μM .

HY-144044

EGFR-IN-30	EGFR	Cancer
EGFR-IN-30 is a potent *EGFR* inhibitor with IC₅₀s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research .

HY-144794

EGFR-IN-46	Apoptosis EGFR FAK	Cancer
EGFR-IN-46 is a potent *EGFR* and FAK dual inhibitor with IC₅₀s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell apoptosis .

HY-156033

EGFR-IN-88	EGFR Apoptosis	Cancer
EGFR-IN-88 (Compound 4i) is an *EGFR* inhibitor (IC₅₀: 87 nM). EGFR-IN-88 shows cytotoxicity against A549 cell with an IC₅₀? of 3.902? μM. EGFR-IN-88 can induce cell apoptosis .

HY-155200

EGFR-IN-84	EGFR	Cancer
EGFR-IN-84 (Compound 6g) is an *EGFR* inhibitor (IC₅₀: 24 nM). EGFR-IN-84 inhibits A549 cell growth (IC₅₀: 1.537 μM). EGFR-IN-84 can be used for research of lung cancer .

HY-138746

EGFR-IN-15	EGFR	Cancer
EGFR-IN-15 (compound I-005) is a *EGFR* inhibitor with an IC₅₀ of 4 nM. EGFR-IN-15 can be used for oncological diseases research .

HY-137786

EGFR-IN-16	EGFR	Cancer
EGFR-IN-16 (compound 3) is a potent *EGFR* inhibitor with pIC₅₀ of 4.85 and 4.74 for EGFR and HER-2, respectively .

HY-147996

EGFR-IN-67	EGFR	Cancer
EGFR-IN-67 (Compound 7d) is a potent *EGFR* inhibitor with an IC₅₀ of 0.34 μM. EGFR-IN-67 shows anticancer activity .

HY-147997

EGFR-IN-68	EGFR	Cancer
EGFR-IN-68 (Compound 8d) is a potent *EGFR* inhibitor with an IC₅₀ of 0.33 μM. EGFR-IN-68 shows anticancer activity .

HY-147995

EGFR-IN-64	EGFR	Cancer
EGFR-IN-64 (Compound 3c) is a potent *EGFR* inhibitor with an IC₅₀ of 0.33 μM. EGFR-IN-64 shows anticancer activity .

HY-162602

EGFR-IN-115	EGFR	Cancer
EGFR-IN-115 (H-13) is an *EGFR* inhibitor, with IC₅₀ of 395.2 nM. EGFR-IN-115 can be used in anti-cancer research .

HY-168064

EGFR-IN-124	EGFR	Cancer
EGFR-IN-124 (compound 10A) is an *EGFR* inhibitor, with IC₅₀ of 0.54 μM. EGFR-IN-124 can be used in anti-cancer research .

HY-163396

EGFR-IN-107	EGFR Apoptosis	Cancer
EGFR-IN-107 (compound 3r) is an orally active *EGFR* inhibitor with IC₅₀ values of 0.4333 μM for EGFR ^WT and 0.0438 μM for EGFR ^L858R/T790M. EGFR-IN-107 has anti-proliferative activity and can inhibit the proliferation of H1975 cells and induce their apoptosis. EGFR-IN-107 can be used in cancer research .

HY-147826

EGFR-IN-60	EGFR Apoptosis	Cancer
EGFR-IN-60 (Compound 7d) shows obvious inhibition of EGFR ^WT, EGFR ^T790M, EGFR ^L858R and JAK3 with IC₅₀s of 83, 26, 53, and 69 nM, respectively. EGFR-IN-60 potently inhibits the growth of H1975 cells harboring EGFR ^T790M mutation (IC₅₀=1.32 µM) over A431 cells overexpressing EGFR ^WT (IC₅₀=4.96 µM). EGFR-IN-60 exhibits good oral absorption, potent and safe antitumor activity. EGFR-IN-60 induces cell death through apoptosis supported by increased Bax/Bcl-2 ratio .

HY-163723

EGFR-IN-116	EGFR VEGFR Topoisomerase	Cancer
EGFR-IN-116 (compound 14D) is an anticancer agent. EGFR-IN-116 against EGFR has the IC₅₀ valuesof *EGFR, VEGFR-2* and Topo II are 0.103 μM, 0.069 μM and 19.74 μM, respectively .

HY-143445

EGFR-IN-48	EGFR	Cancer
EGFR-IN-48 is a potent and orally active *EGFR* inhibitor with IC₅₀s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR ^d19/TM/CS, EGFR ^LR/TM/CS, EGFR ^WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 ^{EGFR del19/T790M/C797S} and PC-9 ^{EGFR del19/T790M/C797S} cells with IC₅₀s of 1.526, 66.7 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6577

Astragaloside VI	Triterpenes other families Leguminosae Terpenoids Source classification Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants	EGFR
Astragaloside VI could activate *EGFR/ERK* signalling pathway to improve wound healing.

HY-N1166

Tephrosin 2 Publications Verification Deguelinol I; Hydroxydeguelin	Structural Classification Flavonoids Ranunculus japonicus Thunb. Classification of Application Fields Isoflavanones Ranunculaceae Source classification Plants Disease Research Fields Cancer	EGFR
Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of *EGFR* and ErbB2 by inducing internalization of the receptors .

HY-13595

Chrysophanol 3 Publications Verification Chrysophanic acid	Quinones Structural Classification Rheum palmatum L. Classification of Application Fields Anthraquinones Polygonaceae Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of *EGFR* and suppresses activation of AKT and mTOR/p70S6K.

HY-14596

Genistein Maximum Cited Publications 43 Publications Verification NPI 031L	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Leguminosae Glycine max (L.) merr Sunscreen Phenols Polyphenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis*, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-113599

Isoprocurcumenol	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Other Diseases Cosmetic Research Plants Disease Research Fields Curcuma comosa Roxb. Zingiberaceae	EGFR ERK Akt
Isoprocurcumenol is a guaiane type sesquiterpene, that can be isolated from Curcuma comosa. Isoprocurcumenol can activate *EGFR* signaling. Isoprocurcumenol increases the phosphorylation of ERK and AKT. Isoprocurcumenol promotes the proliferation of keratinocytes .

HY-B1394

Khellin 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Artemisia cana Pursh Source classification Lignans Phenylpropanoids Umbelliferae Plants Disease Research Fields	EGFR
Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an *EGFR* inhibitor with an IC₅₀ of 0.15 µM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects .

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of *epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀* of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N0211

Cyasterone 1 Publications Verification	Classification of Application Fields Labiatae Source classification Amaranthaceae Plants Laggera crispata (Vahl) Hepper & J. R. I. Wood Disease Research Fields Achyranthes bidentata Steroids Cancer	EGFR Apoptosis
Cyasterone, a natural *EGFR* inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-127067

Yuanhuadin	Structural Classification Terpenoids Thymelaeaceae Source classification Diterpenoids Plants Daphne genkwa Sieb. et Zucc.	Akt EGFR mTOR
Yuanhuadin, extracted from Genkwa Flos Daphne genkwa, has antitumor activity through inhibiting Akt/mTOR and *EGFR* pathways, induce cell-cycle arrest and abortion .

HY-13595R

Chrysophanol (Standard) Chrysophanic acid (Standard)	Quinones Structural Classification Rheum palmatum L. Classification of Application Fields Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	EGFR
Chrysophanol (Standard) is the analytical standard of Chrysophanol. This product is intended for research and analytical applications. Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of *EGFR* and suppresses activation of AKT and mTOR/p70S6K.

HY-14596R

Genistein (Standard) Maximum Cited Publications 43 Publications Verification NPI 031L (Standard)	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Leguminosae Glycine max (L.) merr Sunscreen Phenols Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Cancer	EGFR Autophagy Apoptosis Endogenous Metabolite
Genistein (Standard) is the analytical standard of Genistein. This product is intended for research and analytical applications. Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., *EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis*, the cell cycle, and angiogenesis and inhibiting metastasis.

HY-B1394R

Khellin (Standard)	Structural Classification Artemisia cana Pursh Source classification Lignans Phenylpropanoids Umbelliferae Plants	EGFR
Khellin (Standard) is the analytical standard of Khellin. This product is intended for research and analytical applications. Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an EGFR inhibitor with an IC50 of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects .

HY-N2450

Sulforaphene	Structural Classification Natural Products Classification of Application Fields Source classification Plants Brassicaceae Disease Research Fields Cancer Raphanus sativus Linn.	Apoptosis EGFR ERK NF-κB Microtubule/Tubulin
Sulforaphene, isolated from radish seeds, exhibits an ED₅₀ against velvetleaf seedlings approximately 2 x 10 ^-4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting *EGFR, p-ERK1/2, NF‐κB* and other signals .

HY-N0211R

Cyasterone (Standard)	Structural Classification Labiatae Source classification Amaranthaceae Plants Laggera crispata (Vahl) Hepper & J. R. I. Wood Achyranthes bidentata Steroids	EGFR Apoptosis
Cyasterone (Standard) is the analytical standard of Cyasterone. This product is intended for research and analytical applications. Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .

HY-N2409

Delphinidin chloride	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Plants Anthocyans Flavonoids Microorganisms other families Solanum melongena L. Phenols Polyphenols Solanaceae Disease Research Fields Cancer	Apoptosis EGFR JAK STAT
Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC₅₀: 1.3 μM), shutting down downstream signaling cascades .

HY-N12726

Halociline	Structural Classification Microorganisms Marine natural products Source classification Phenols Marine microorganism	p38 MAPK MMP
Halociline, a derivative of alkaloids, that can be isolated from the marine fungus Penicillium griseofulvum. Halociline targets MAPK1, MMP-9, and PIK3CA in gastric cancer cells, potentially mediated by diverse pathways including cancer, lipid metabolism, atherosclerosis, and EGFR tyrosine kinase inhibitor resistance. Halociline possesses antimicrobial, antioxidant and biofilm inhibitory activities .

HY-N4201

β-Hydroxyisovalerylshikonin	Quinones Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer	EGFR Src
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC₅₀s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells .

HY-16558

Butein 4 Publications Verification 2’,3,4,4’-tetrahydroxy Chalcone	Structural Classification Chalcones Flavonoids other families Classification of Application Fields Anti-aging Source classification Phenols Polyphenols Plants Disease Research Fields Cancer	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein is a cAMP-specific PDE inhibitor with an IC₅₀ of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC₅₀s of 16 and 65 μM for *EGFR* and p60 ^c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N2510

Myristicin Myristicine	Structural Classification Simple Phenylpropanols Source classification Myristicaceae Phenylpropanoids Plants Myristica fragrans Houtt.	5-HT Receptor EGFR ERK Apoptosis Bacterial
Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the *EGFR/ERK* signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-N2409R

Delphinidin chloride (Standard)	Structural Classification Anthocyans Flavonoids Microorganisms other families Solanum melongena L. Source classification Phenols Polyphenols Solanaceae Plants	Apoptosis EGFR JAK STAT
Delphinidin (chloride) (Standard) is the analytical standard of Delphinidin (chloride). This product is intended for research and analytical applications. Delphinidin chloride is an anthocyanin isolated from berries and red wine. Delphinidin chloride exhibits endothelium-dependent vasodilation and anticancer activity. Delphinidin chloride also modulates JAK/STAT3 and MAPK signaling, thereby inducing apoptosis in HCT116 cells. Delphinidin chloride is also a potent inhibitor of EGFR (IC50: 1.3 μM), shutting down downstream signaling cascades .

HY-108016

Peruvoside Encordin	Apocynaceae Triterpenes Structural Classification Terpenoids Source classification Thevetia peruviana (Pers.) K. Schum. Plants	Src PI3K JNK STAT EGFR Apoptosis Autophagy
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and *EGFR. Peruvoside induces apoptosis* and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

HY-16558R

Butein (Standard)	Structural Classification Chalcones Flavonoids other families Source classification Phenols Polyphenols Plants	EGFR Autophagy Apoptosis Phosphodiesterase (PDE)
Butein (Standard) is the analytical standard of Butein. This product is intended for research and analytical applications. Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4 . Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60c-src in HepG2 cells . Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a . Butein is a SIRT1 activator (STAC).

HY-N2510R

Myristicin (Standard)	Structural Classification Simple Phenylpropanols Source classification Myristicaceae Phenylpropanoids Plants Myristica fragrans Houtt.	5-HT Receptor EGFR ERK Apoptosis Bacterial
Myristicin (Standard) is the analytical standard of Myristicin. This product is intended for research and analytical applications. Myristicine is an orally bioavailable serotonin receptor antagonist and weak monoamine oxidase (MAO) inhibitor. Myristicine also exerts anti-cancer effects on gastric cancer cells by inhibiting the EGFR/ERK signaling pathway. Myristicine is the main component of nutmeg essential oil and has anti-cancer, anti-proliferative, antibacterial, anti-inflammatory and apoptosis-inducing effects. Myristicine abuse can produce hallucinogenic effects, organ damage, etc .

HY-N0281

Daphnetin 3 Publications Verification 7,8-Dihydroxycoumarin	Structural Classification Daphne Classification of Application Fields Thymelaeaceae Source classification Coumarins Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Cancer	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite
Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1?, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-108052

Delphinidin 3-glucoside chloride Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Classification of Application Fields Hibiscus sabdariffa Linn. Source classification Plants Disease Research Fields Cancer	EGFR Apoptosis Akt
Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC₅₀ of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC₅₀ of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

HY-N0281R

Daphnetin (Standard)	Structural Classification Daphne Thymelaeaceae Source classification Coumarins Phenols Polyphenols Phenylpropanoids Plants	EGFR PKA PKC Autophagy Apoptosis AMPK Akt mTOR Reactive Oxygen Species Caspase Bcl-2 Family PARP Parasite
Daphnetin (Standard) is the analytical standard of Daphnetin. This product is intended for research and analytical applications. Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC₅₀s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1 , ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research .

HY-108052R

Delphinidin 3-glucoside (chloride) (Standard)	Malvaceae Structural Classification Anthocyans Flavonoids Microorganisms Hibiscus sabdariffa Linn. Source classification Plants	EGFR Apoptosis Akt
Delphinidin 3-glucoside (chloride) (Standard) is the analytical standard of Delphinidin 3-glucoside (chloride). This product is intended for research and analytical applications. Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in Hibiscus sabdariffa extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL) . Delphinidin 3-glucoside chloride exerts phytoestrogen activity by binding to ERβ, with an IC50 of 9.7 μM . Delphinidin-3-O-glucoside chloride inhibits EGFR with an IC50 of 2.37 µM . Delphinidin 3-glucoside chloride exhibits antitumor effects through pAKT/IRF1/HOTAIR pathway. Delphinidin 3-glucoside chloride exhibits efficacy against oxidative stress, inhibits platelet activation and endothelial dysfunction .

Cat. No.	Product Name	Chemical Structure

HY-50896S1

Erlotinib-13C6
Erlotinib- ¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

HY-12008S1

Erlotinib-13C6 hydrochloride
Erlotinib- ¹³C₆ (hydrochloride) is the ¹³C labeled Erlotinib Hydrochloride[1]. Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM[2]. Erlotinib-13C6 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10260S2

Vandetanib-13C6
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-13653S

(+/-)-Epigallocatechin Gallate-13C3

(+/-)-Epigallocatechin Gallate- ¹³C₃ is the ¹³C-labeled (-)-Epigallocatechin Gallate. (-)-Epigallocatechin Gallate is a tea flavonoid with potent antioxidant, antiinflammatory, and anticarcinogenic properties. (-)-Epigallocatechin Gallate is reported to inhibit EGFR signaling and thereby exert anticancer effects[1]. (-)-Epigallocatechin Gallate (EGCG) is a glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) inhibitor. Epigallocatechin-3-gallate induces oxidative phosphorylation (OXPHOS) by activating cytochrome c oxidase.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks